所有图片(1)
别名:
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en
经验公式（希尔记法）:
C12H20N4O7
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
旋光性
[α]/D +30 to +40°, c = 1 in H2O
颜色
white to beige
溶解性
H2O: 10 mg/mL, clear
储存温度
room temp
SMILES字符串
CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
InChI
1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
InChI key
ARAIBEBZBOPLMB-UFGQHTETSA-N
正在寻找类似产品? 访问 产品对比指南
应用
Zanamivir has been used:
- as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
- as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
- as an antiviral to study its effects on influenza B virus by plaque reduction assay
生化/生理作用
Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.
Zanamivir is an influenza viral neuraminidase inhibitor.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Carl J Heneghan et al.
BMJ (Clinical research ed.), 348, g2547-g2547 (2014-05-09)
To describe the potential benefits and harms of zanamivir. Systematic review of clinical study reports of randomised placebo controlled trials and regulatory information Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Randomised placebo controlled trials
Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Javier Magano
Chemical reviews, 109(9), 4398-4438 (2009-06-23)
Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.
Benjamin O Fulton et al.
Journal of virology, 89(23), 12226-12231 (2015-09-25)
Influenza B virus is a human pathogen responsible for significant health and economic burden. Research into this pathogen has been limited by the lack of reporter viruses. Here we describe the development of both a replication-competent fluorescent influenza B reporter
Emi Takashita et al.
Antimicrobial agents and chemotherapy, 59(5), 2607-2617 (2015-02-19)
Between September 2013 and July 2014, 2,482 influenza 2009 pandemic A(H1N1) [A(H1N1)pdm09] viruses were screened in Japan for the H275Y substitution in their neuraminidase (NA) protein, which confers cross-resistance to oseltamivir and peramivir. We found that a large cluster of
Zanamivir
Waghorn S L and Goa K L
Drugs, 55(5), 721-725 (1998)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门